S&P 500 7,722.72 +0.73%
Nasdaq 27,190.86 +1.19%
S&P/TSX 35,502.65 +0.99%
Apple 333.69 +1.02%
Nvidia 233.95 +1.34%
Microsoft 517.53 +0.92%
Shopify 215.86 +1.77%
Royal Bank 278.91 +0.38%
CAD/USD 0.7019 −0.19%
CLOSED · 04:45 ET
Market ClerkRecap
Sat Oct 3 · markets closed5 signals on Oct 2306 insider buys this week · $10330.5BCIRO short report next: Oct 15The week ahead

VIR

Vir Biotechnology, Inc.
NASDAQ · HEALTH CARE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
11.17
−0.12 −1.06%
USD · close Oct 2

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

MKT CAP $1.9BP/E —DIV YIELD —FCF YIELD -10.77%REV TTM $303.2M +1495.9%NET INCOME −$251.7MNET CASH —52W 5.12 – 11.63SEC XBRL · TTM TO Invalid Date

Who holds it

SEC 13F · LATEST QUARTER PER FUND
None of the 15 tracked funds disclose VIR in their latest 13F. The funds we follow.

13F filings cover US-listed holdings and arrive up to 45 days after quarter end, so positions may have changed since.

Stakes of 5% or more

SCHEDULE 13D / 13G · LATEST PER HOLDER · TWO YEARS
No 13D or 13G filing on VIR in the last two years from the filings we read (13G only for companies we track; the sweep began Sep 2026).

A 13D means the holder crossed 5% with intent beyond passive ownership and had to state a purpose; a 13G is the passive version. Every new 13D on tracked companies.

Watch VIR. Know when insiders buy.
One email the day a filing lands. Free.